MX356373B - Composiciones que comprenden un agente antibacterial y tazobactam. - Google Patents
Composiciones que comprenden un agente antibacterial y tazobactam.Info
- Publication number
- MX356373B MX356373B MX2013013079A MX2013013079A MX356373B MX 356373 B MX356373 B MX 356373B MX 2013013079 A MX2013013079 A MX 2013013079A MX 2013013079 A MX2013013079 A MX 2013013079A MX 356373 B MX356373 B MX 356373B
- Authority
- MX
- Mexico
- Prior art keywords
- tazobactam
- antibacterial agent
- compositions
- gram
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describe una composición farmacéutica que comprende un agente antibacteriano y tazobactam; donde la proporción de tazobactam con respecto al agente antibacteriano en la composición está en la escala de alrededor de 0.5 a alrededor de 2 g de tazobactam por gramo del agente antibacteriano.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1587MU2011 | 2011-05-28 | ||
PCT/IB2011/053398 WO2012164358A1 (en) | 2011-05-28 | 2011-08-01 | Compositions comprising antibacterial agent and tazobactam |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013013079A MX2013013079A (es) | 2013-12-06 |
MX356373B true MX356373B (es) | 2018-05-25 |
Family
ID=44681394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013013079A MX356373B (es) | 2011-05-28 | 2011-08-01 | Composiciones que comprenden un agente antibacterial y tazobactam. |
Country Status (18)
Country | Link |
---|---|
US (1) | US10525043B2 (es) |
EP (2) | EP3412289A1 (es) |
JP (1) | JP5767745B2 (es) |
KR (3) | KR20170032480A (es) |
CN (2) | CN109481439A (es) |
AU (1) | AU2011369802B2 (es) |
BR (1) | BR112013030282B1 (es) |
CA (1) | CA2835907C (es) |
DK (1) | DK2714034T3 (es) |
ES (1) | ES2690725T3 (es) |
HU (1) | HUE040049T2 (es) |
MX (1) | MX356373B (es) |
NZ (1) | NZ616692A (es) |
PL (1) | PL2714034T3 (es) |
PT (1) | PT2714034T (es) |
RU (1) | RU2593363C2 (es) |
WO (1) | WO2012164358A1 (es) |
ZA (1) | ZA201307837B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017508769A (ja) * | 2014-03-29 | 2017-03-30 | ウォックハート リミテッド | セフェピムまたはスルバクタムを含む医薬組成物 |
CN107847501A (zh) * | 2016-03-31 | 2018-03-27 | 沃克哈特有限公司 | 抗菌组合物以及方法 |
BR112017022864A2 (pt) * | 2016-03-31 | 2018-07-17 | Wockhardt Ltd | composições antibacterianas |
CA2983250C (en) * | 2016-03-31 | 2021-04-27 | Wockhardt Limited | Antibacterial compositions |
TWI798268B (zh) * | 2017-10-05 | 2023-04-11 | 日商富士軟片股份有限公司 | 新穎的2-羧基青黴烷化合物或其鹽、含有該等的醫藥組成物及其用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1565456A (zh) * | 2003-06-14 | 2005-01-19 | 张哲峰 | 一种头孢吡肟抗菌组合药物 |
CN1565455A (zh) * | 2003-07-04 | 2005-01-19 | 成都博瑞医药科技开发有限公司 | 治疗产超广谱β-内酰胺酶细菌感染用的抗菌素组合物 |
KR20070067189A (ko) * | 2004-12-02 | 2007-06-27 | 비너스 레머디스 리미티드 | 주사제에 유용한 베타-락타마제 억제제를 이용한베타-락타마제-매개 항생제 내성에 대처하기 위한 조성물 |
CN100565455C (zh) | 2005-10-21 | 2009-12-02 | 神基科技股份有限公司 | 多媒体电脑系统及快速启始该系统播放多媒体数据的方法 |
WO2007086014A1 (en) * | 2006-01-25 | 2007-08-02 | Jegannathan Srinivas | Formulation comprising cefpirome, tazobactam and linezolid |
WO2007086011A1 (en) * | 2006-01-25 | 2007-08-02 | Jegannathan Srinivas | Formulation comprising cefepime, tazobactam and linezolid |
CN100565456C (zh) | 2006-08-25 | 2009-12-02 | 佛山市顺德区顺达电脑厂有限公司 | 缩短计算机开机时间的方法 |
EP1958630A1 (en) * | 2007-02-13 | 2008-08-20 | LEK Pharmaceuticals d.d. | Antibacterial combination of a tricyclic carbapenem and an antibiotic |
BRPI0916885B8 (pt) * | 2008-08-28 | 2021-05-25 | Astrazeneca Ab | composição farmacêutica |
-
2011
- 2011-08-01 RU RU2013157933/15A patent/RU2593363C2/ru active
- 2011-08-01 BR BR112013030282-8A patent/BR112013030282B1/pt active IP Right Grant
- 2011-08-01 KR KR1020177006744A patent/KR20170032480A/ko active Application Filing
- 2011-08-01 EP EP18184190.9A patent/EP3412289A1/en not_active Withdrawn
- 2011-08-01 CA CA2835907A patent/CA2835907C/en active Active
- 2011-08-01 MX MX2013013079A patent/MX356373B/es active IP Right Grant
- 2011-08-01 CN CN201811566372.5A patent/CN109481439A/zh active Pending
- 2011-08-01 DK DK11761404.0T patent/DK2714034T3/en active
- 2011-08-01 EP EP11761404.0A patent/EP2714034B1/en active Active
- 2011-08-01 HU HUE11761404A patent/HUE040049T2/hu unknown
- 2011-08-01 NZ NZ616692A patent/NZ616692A/en not_active IP Right Cessation
- 2011-08-01 WO PCT/IB2011/053398 patent/WO2012164358A1/en active Application Filing
- 2011-08-01 US US14/111,627 patent/US10525043B2/en active Active - Reinstated
- 2011-08-01 JP JP2014504401A patent/JP5767745B2/ja active Active
- 2011-08-01 CN CN201180071223.1A patent/CN103608013A/zh active Pending
- 2011-08-01 AU AU2011369802A patent/AU2011369802B2/en active Active
- 2011-08-01 ES ES11761404.0T patent/ES2690725T3/es active Active
- 2011-08-01 PT PT11761404T patent/PT2714034T/pt unknown
- 2011-08-01 KR KR1020187003773A patent/KR101850265B1/ko active IP Right Grant
- 2011-08-01 KR KR1020137029926A patent/KR20140035376A/ko not_active Application Discontinuation
- 2011-08-01 PL PL11761404T patent/PL2714034T3/pl unknown
-
2013
- 2013-10-21 ZA ZA2013/07837A patent/ZA201307837B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2014514305A (ja) | 2014-06-19 |
HUE040049T2 (hu) | 2019-02-28 |
KR20180016645A (ko) | 2018-02-14 |
AU2011369802B2 (en) | 2016-09-08 |
DK2714034T3 (en) | 2018-10-08 |
CN103608013A (zh) | 2014-02-26 |
EP2714034B1 (en) | 2018-07-25 |
AU2011369802A1 (en) | 2013-10-31 |
WO2012164358A1 (en) | 2012-12-06 |
BR112013030282B1 (pt) | 2020-09-29 |
RU2593363C2 (ru) | 2016-08-10 |
CN109481439A (zh) | 2019-03-19 |
KR20170032480A (ko) | 2017-03-22 |
ES2690725T3 (es) | 2018-11-22 |
RU2013157933A (ru) | 2015-07-10 |
PT2714034T (pt) | 2018-10-30 |
US20140162995A1 (en) | 2014-06-12 |
CA2835907C (en) | 2017-03-21 |
BR112013030282A2 (pt) | 2017-11-07 |
US10525043B2 (en) | 2020-01-07 |
EP3412289A1 (en) | 2018-12-12 |
ZA201307837B (en) | 2015-01-28 |
PL2714034T3 (pl) | 2018-12-31 |
CA2835907A1 (en) | 2012-12-06 |
NZ616692A (en) | 2015-07-31 |
KR20140035376A (ko) | 2014-03-21 |
KR101850265B1 (ko) | 2018-04-18 |
JP5767745B2 (ja) | 2015-08-19 |
MX2013013079A (es) | 2013-12-06 |
EP2714034A1 (en) | 2014-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20180102B1 (ar) | مركب صيدلاني | |
MY176814A (en) | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | |
MX2012012837A (es) | Composiciones farmaceuticas y metodos para su elaboracion. | |
MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
MY188960A (en) | Cyclic boronic acid ester derivatives and therapeutic uses thereof | |
EP3725321A4 (en) | COMPOSITION WITH A BACTERIUM OF THE GENUS BIFIDOBACTERIUM AS THE ACTIVE SUBSTANCE | |
UA105766C2 (uk) | Фармацевтична композиція, яка містить сіль стронцію, вітамін d і циклодекстрин | |
MX2013001677A (es) | Formulaciones estables de linaclotida. | |
WO2011131943A8 (en) | Pharmaceutical compositions | |
MX2019012939A (es) | Formulaciones que contienen linaclotida para administracion oral. | |
TN2012000488A1 (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
MY168212A (en) | A new therapeutical composition containing apomorphine as active ingredient | |
MX2014010433A (es) | Nueva forma cristalina de sulfato de sitagliptina. | |
GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
MX2013013079A (es) | Composiciones que comprenden un agente antibacterial y tazobactam. | |
TR201009167A2 (tr) | Sefalosporin içeren farmasötik granüller. | |
IN2014DN03010A (es) | ||
EP2611799A4 (en) | PHARMACEUTICAL COMPOSITIONS OF LINEZOLID | |
WO2012093973A3 (en) | Compositions in the form of tablets comprising acarbose | |
EP2568810A4 (en) | COMPOSITIONS OF DARUNAVIR | |
WO2015071299A3 (en) | Stable pharmaceutical glycylcycline compositions | |
WO2012007758A3 (en) | Pharmaceutical formulations | |
PH12015501428A1 (en) | Antibacterial compounds | |
WO2011092655A3 (en) | Mentha suaveolens essential oil and therapeutic activities thereof | |
BR112014015193A2 (pt) | composição enriquecida com glicoproteína como um aditivo para alimento e/ou ração e/ou como um agente terapêutico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |